Business Wire · LIVN · October 23, 2026

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy

Get the app for more

Explore stock news, insights and company research.